Skip to content

Study · Animal study (in vivo) · calf (bovine) · 2012

3 results

Antibody fusions reduce onset of experimental Cryptosporidium parvum infection in calves.

Imboden M, Schaefer DA, Bremel RD, Homan EJ, Riggs MW

Veterinary parasitology6 Mar 2012Cited by 12 (Europe PMC)

PMID22455725 (opens in a new tab)PMCIDPMC3387522 (opens in a new tab)DOI10.1016/j.vetpar.2012.02.014 (opens in a new tab)PepBankPUB-22455725
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In neonatal calves infected with Cryptosporidium parvum, the antibody-LL37 fusion 4H9-G1-LL37 reduced disease severity compared with control animals.

    In plain wordsIn calves infected with a gut parasite, an antibody-LL37 fusion made the disease less severe than in control animals.

    Peptide
    LL-37
    Outcome
    DecreaseDisease severity
    Study

    calf (bovine)n: not reported in source

    experimental Cryptosporidium parvum infection
    Comparator
    Control animals
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    Dose not stated · four daysAs given in this study (calf (bovine)).

    Source sentences

    Summary
    This resulted in reduced severity of the disease when compared to control animals.
    1 context sentence
    Summary · context
    Neonatal calves were challenged with C. parvum oocysts and concomitantly treated with antibody-biocide fusion 4H9-G1-LL37 over the course of four days.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In neonatal calves infected with Cryptosporidium parvum, overall clinical health parameters showed significant improvement in animals treated with the antibody-LL37 fusion 4H9-G1-LL37 versus control animals.

    In plain wordsIn calves infected with a gut parasite, an antibody-LL37 fusion improved overall health signs compared with control animals.

    Peptide
    LL-37
    Outcome
    Not applicableOverall clinical health parameters
    Study

    calf (bovine)n: not reported in source

    experimental Cryptosporidium parvum infection
    Comparator
    Control animals
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    Dose not stated · four daysAs given in this study (calf (bovine)).

    Source sentences

    Summary
    Overall clinical health parameters showed significant improvement in treated animals.
    1 context sentence
    Summary · context
    Neonatal calves were challenged with C. parvum oocysts and concomitantly treated with antibody-biocide fusion 4H9-G1-LL37 over the course of four days.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In neonatal calves infected with Cryptosporidium parvum, oocyst shedding was reduced in animals treated with the antibody-LL37 fusion 4H9-G1-LL37 compared with control animals.

    In plain wordsIn calves infected with a gut parasite, an antibody-LL37 fusion lowered parasite shedding compared with control animals.

    Peptide
    LL-37
    Outcome
    DecreaseOocyst shedding
    Study

    calf (bovine)n: not reported in source

    experimental Cryptosporidium parvum infection
    Comparator
    Control animals
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    Dose not stated · four daysAs given in this study (calf (bovine)).

    Source sentences

    Summary
    Oocyst shedding was reduced in treated when compared to control animals.
    1 context sentence
    Summary · context
    Neonatal calves were challenged with C. parvum oocysts and concomitantly treated with antibody-biocide fusion 4H9-G1-LL37 over the course of four days.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:57 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.